Tag: HY-091
AFT Pharmaceuticals spearheads progress in women’s health with Hyloris partnership
AFT Pharmaceuticals announced its partnership with Hyloris Pharmaceuticals, based in Belgium, to develop a novel treatment, HY-091, for Vulvar Lichen Sclerosus (VLS), addressing the critical need for effective solutions in an area where approved treatments are limited.
Featured Article
Beyond insights: CRM’s transformative role in sustainable manufacturing
Manufacturing companies worldwide are increasingly gearing up for a significant transformation with environmental sustainability at the centre. This comes amid stronger environmental regulations, a shift in consumer behaviour, and the industrial sector delves deeper into Industry 4.0.
